Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N. (Niki)|||/items/36602b54-c423-4e2b-bda5-100f1ac9888a; Gonzalez-Cao, M. (María)|||/items/a92f6c0c-bc3c-46c9-9d59-a6174bc08c57; Crespo, G. (Guillermo)|||/items/0a956c2d-2ab1-46ca-bd33-c7a904a8c5fd; Drozdowskyj, A. (Ana)|||/items/6bf1ad03-c22f-4879-99a4-614a5cbfa233; Aldeguer, E. (Erika)|||/items/3137e07c-24f0-4bbe-b2f9-e70719621944; Gimenez-Capitan, A. (Ana)|||/items/bfbf646d-9cd3-4c6a-860d-899f0fdd381c; Teixidó, C. (Cristina)|||/items/aa9cf171-f6e0-40c4-8abe-8c092f959fb2; Molina-Vila, M.A. (Miguel Angel)|||/items/3882633e-1ab4-40d8-95d7-d59b6778588d; Viteri, S. (S.)|||/items/a18abe0d-fb47-4afa-ae94-cc2b4bced9f0; Llanos-Gil, M. (Maria) de los|||/items/6a68bee0-cefd-4f2a-97f4-d5baa3afa4f3; Martin-Algarra, S. (Salvador)|||/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc; Perez-Ruiz, E. (Elisabeth)|||/items/d83c356b-f521-479f-83df-13785e169cc1; Marquez-Rodas, I. (Iván)|||/items/a59fa425-b0b0-47e3-9eb6-0543b7132a0c; Rodríguez-Abreu, D. (Delvys)|||/items/ecc8f1ae-480b-428f-ac12-bf672f06fa67; Blanco, R. (Remedios)|||/items/7644d971-8a63-4eda-9012-fbd925d700cf; Puertolas, T. (Teresa)|||/items/95b9743f-10df-4b17-acb4-54380eae921b; Royo, M.A. (María Ángeles)|||/items/70abc417-2e22-4f7c-857a-bf26dc742cdb; Rosell, R. (Rafael)|||/items/771e36b5-84e0-4ac6-9009-324f454c04b0

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lun...

ver descrição completa

Detalhes bibliográficos
Autores:	Karachaliou, N. (Niki)\|\|\|/items/36602b54-c423-4e2b-bda5-100f1ac9888a, Gonzalez-Cao, M. (María)\|\|\|/items/a92f6c0c-bc3c-46c9-9d59-a6174bc08c57, Crespo, G. (Guillermo)\|\|\|/items/0a956c2d-2ab1-46ca-bd33-c7a904a8c5fd, Drozdowskyj, A. (Ana)\|\|\|/items/6bf1ad03-c22f-4879-99a4-614a5cbfa233, Aldeguer, E. (Erika)\|\|\|/items/3137e07c-24f0-4bbe-b2f9-e70719621944, Gimenez-Capitan, A. (Ana)\|\|\|/items/bfbf646d-9cd3-4c6a-860d-899f0fdd381c, Teixidó, C. (Cristina)\|\|\|/items/aa9cf171-f6e0-40c4-8abe-8c092f959fb2, Molina-Vila, M.A. (Miguel Angel)\|\|\|/items/3882633e-1ab4-40d8-95d7-d59b6778588d, Viteri, S. (S.)\|\|\|/items/a18abe0d-fb47-4afa-ae94-cc2b4bced9f0, Llanos-Gil, M. (Maria) de los\|\|\|/items/6a68bee0-cefd-4f2a-97f4-d5baa3afa4f3, Martin-Algarra, S. (Salvador)\|\|\|/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc, Perez-Ruiz, E. (Elisabeth)\|\|\|/items/d83c356b-f521-479f-83df-13785e169cc1, Marquez-Rodas, I. (Iván)\|\|\|/items/a59fa425-b0b0-47e3-9eb6-0543b7132a0c, Rodríguez-Abreu, D. (Delvys)\|\|\|/items/ecc8f1ae-480b-428f-ac12-bf672f06fa67, Blanco, R. (Remedios)\|\|\|/items/7644d971-8a63-4eda-9012-fbd925d700cf, Puertolas, T. (Teresa)\|\|\|/items/95b9743f-10df-4b17-acb4-54380eae921b, Royo, M.A. (María Ángeles)\|\|\|/items/70abc417-2e22-4f7c-857a-bf26dc742cdb, Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0
Formato:	artículo
Fecha de publicación:	2018
País:	España
Recursos:	Universidad de Navarra
Repositorio:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglés
OAI Identifier:	oai:dadun.unav.edu:10171/65643
Acesso em linha:	https://hdl.handle.net/10171/65643
Access Level:	acceso abierto
Palavra-chave:	Immunotherapy Interferon-gamma PD-1 PD-L1 Lung cancer Melanoma

id	ES_2f4b50ebcd37bb1fe5cb9c00803a378b
oai_identifier_str	oai:dadun.unav.edu:10171/65643
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patientsKarachaliou, N. (Niki)\|\|\|/items/36602b54-c423-4e2b-bda5-100f1ac9888aGonzalez-Cao, M. (María)\|\|\|/items/a92f6c0c-bc3c-46c9-9d59-a6174bc08c57Crespo, G. (Guillermo)\|\|\|/items/0a956c2d-2ab1-46ca-bd33-c7a904a8c5fdDrozdowskyj, A. (Ana)\|\|\|/items/6bf1ad03-c22f-4879-99a4-614a5cbfa233Aldeguer, E. (Erika)\|\|\|/items/3137e07c-24f0-4bbe-b2f9-e70719621944Gimenez-Capitan, A. (Ana)\|\|\|/items/bfbf646d-9cd3-4c6a-860d-899f0fdd381cTeixidó, C. (Cristina)\|\|\|/items/aa9cf171-f6e0-40c4-8abe-8c092f959fb2Molina-Vila, M.A. (Miguel Angel)\|\|\|/items/3882633e-1ab4-40d8-95d7-d59b6778588dViteri, S. (S.)\|\|\|/items/a18abe0d-fb47-4afa-ae94-cc2b4bced9f0Llanos-Gil, M. (Maria) de los\|\|\|/items/6a68bee0-cefd-4f2a-97f4-d5baa3afa4f3Martin-Algarra, S. (Salvador)\|\|\|/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0ccPerez-Ruiz, E. (Elisabeth)\|\|\|/items/d83c356b-f521-479f-83df-13785e169cc1Marquez-Rodas, I. (Iván)\|\|\|/items/a59fa425-b0b0-47e3-9eb6-0543b7132a0cRodríguez-Abreu, D. (Delvys)\|\|\|/items/ecc8f1ae-480b-428f-ac12-bf672f06fa67Blanco, R. (Remedios)\|\|\|/items/7644d971-8a63-4eda-9012-fbd925d700cfPuertolas, T. (Teresa)\|\|\|/items/95b9743f-10df-4b17-acb4-54380eae921bRoyo, M.A. (María Ángeles)\|\|\|/items/70abc417-2e22-4f7c-857a-bf26dc742cdbRosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0ImmunotherapyInterferon-gammaPD-1PD-L1Lung cancerMelanomaBackground: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined.SAGE PublicationsDadun. Depósito Académico Digital Universidad de Navarra20232023-03-0920182018-01-0120182018-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/65643reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/656432026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
title	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
spellingShingle	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients Karachaliou, N. (Niki)\|\|\|/items/36602b54-c423-4e2b-bda5-100f1ac9888a Immunotherapy Interferon-gamma PD-1 PD-L1 Lung cancer Melanoma
title_short	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
title_full	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
title_fullStr	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
title_full_unstemmed	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
title_sort	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
dc.creator.none.fl_str_mv	Karachaliou, N. (Niki)\|\|\|/items/36602b54-c423-4e2b-bda5-100f1ac9888a Gonzalez-Cao, M. (María)\|\|\|/items/a92f6c0c-bc3c-46c9-9d59-a6174bc08c57 Crespo, G. (Guillermo)\|\|\|/items/0a956c2d-2ab1-46ca-bd33-c7a904a8c5fd Drozdowskyj, A. (Ana)\|\|\|/items/6bf1ad03-c22f-4879-99a4-614a5cbfa233 Aldeguer, E. (Erika)\|\|\|/items/3137e07c-24f0-4bbe-b2f9-e70719621944 Gimenez-Capitan, A. (Ana)\|\|\|/items/bfbf646d-9cd3-4c6a-860d-899f0fdd381c Teixidó, C. (Cristina)\|\|\|/items/aa9cf171-f6e0-40c4-8abe-8c092f959fb2 Molina-Vila, M.A. (Miguel Angel)\|\|\|/items/3882633e-1ab4-40d8-95d7-d59b6778588d Viteri, S. (S.)\|\|\|/items/a18abe0d-fb47-4afa-ae94-cc2b4bced9f0 Llanos-Gil, M. (Maria) de los\|\|\|/items/6a68bee0-cefd-4f2a-97f4-d5baa3afa4f3 Martin-Algarra, S. (Salvador)\|\|\|/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc Perez-Ruiz, E. (Elisabeth)\|\|\|/items/d83c356b-f521-479f-83df-13785e169cc1 Marquez-Rodas, I. (Iván)\|\|\|/items/a59fa425-b0b0-47e3-9eb6-0543b7132a0c Rodríguez-Abreu, D. (Delvys)\|\|\|/items/ecc8f1ae-480b-428f-ac12-bf672f06fa67 Blanco, R. (Remedios)\|\|\|/items/7644d971-8a63-4eda-9012-fbd925d700cf Puertolas, T. (Teresa)\|\|\|/items/95b9743f-10df-4b17-acb4-54380eae921b Royo, M.A. (María Ángeles)\|\|\|/items/70abc417-2e22-4f7c-857a-bf26dc742cdb Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0
author	Karachaliou, N. (Niki)\|\|\|/items/36602b54-c423-4e2b-bda5-100f1ac9888a
author_facet	Karachaliou, N. (Niki)\|\|\|/items/36602b54-c423-4e2b-bda5-100f1ac9888a Gonzalez-Cao, M. (María)\|\|\|/items/a92f6c0c-bc3c-46c9-9d59-a6174bc08c57 Crespo, G. (Guillermo)\|\|\|/items/0a956c2d-2ab1-46ca-bd33-c7a904a8c5fd Drozdowskyj, A. (Ana)\|\|\|/items/6bf1ad03-c22f-4879-99a4-614a5cbfa233 Aldeguer, E. (Erika)\|\|\|/items/3137e07c-24f0-4bbe-b2f9-e70719621944 Gimenez-Capitan, A. (Ana)\|\|\|/items/bfbf646d-9cd3-4c6a-860d-899f0fdd381c Teixidó, C. (Cristina)\|\|\|/items/aa9cf171-f6e0-40c4-8abe-8c092f959fb2 Molina-Vila, M.A. (Miguel Angel)\|\|\|/items/3882633e-1ab4-40d8-95d7-d59b6778588d Viteri, S. (S.)\|\|\|/items/a18abe0d-fb47-4afa-ae94-cc2b4bced9f0 Llanos-Gil, M. (Maria) de los\|\|\|/items/6a68bee0-cefd-4f2a-97f4-d5baa3afa4f3 Martin-Algarra, S. (Salvador)\|\|\|/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc Perez-Ruiz, E. (Elisabeth)\|\|\|/items/d83c356b-f521-479f-83df-13785e169cc1 Marquez-Rodas, I. (Iván)\|\|\|/items/a59fa425-b0b0-47e3-9eb6-0543b7132a0c Rodríguez-Abreu, D. (Delvys)\|\|\|/items/ecc8f1ae-480b-428f-ac12-bf672f06fa67 Blanco, R. (Remedios)\|\|\|/items/7644d971-8a63-4eda-9012-fbd925d700cf Puertolas, T. (Teresa)\|\|\|/items/95b9743f-10df-4b17-acb4-54380eae921b Royo, M.A. (María Ángeles)\|\|\|/items/70abc417-2e22-4f7c-857a-bf26dc742cdb Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0
author_role	author
author2	Gonzalez-Cao, M. (María)\|\|\|/items/a92f6c0c-bc3c-46c9-9d59-a6174bc08c57 Crespo, G. (Guillermo)\|\|\|/items/0a956c2d-2ab1-46ca-bd33-c7a904a8c5fd Drozdowskyj, A. (Ana)\|\|\|/items/6bf1ad03-c22f-4879-99a4-614a5cbfa233 Aldeguer, E. (Erika)\|\|\|/items/3137e07c-24f0-4bbe-b2f9-e70719621944 Gimenez-Capitan, A. (Ana)\|\|\|/items/bfbf646d-9cd3-4c6a-860d-899f0fdd381c Teixidó, C. (Cristina)\|\|\|/items/aa9cf171-f6e0-40c4-8abe-8c092f959fb2 Molina-Vila, M.A. (Miguel Angel)\|\|\|/items/3882633e-1ab4-40d8-95d7-d59b6778588d Viteri, S. (S.)\|\|\|/items/a18abe0d-fb47-4afa-ae94-cc2b4bced9f0 Llanos-Gil, M. (Maria) de los\|\|\|/items/6a68bee0-cefd-4f2a-97f4-d5baa3afa4f3 Martin-Algarra, S. (Salvador)\|\|\|/items/2fba8e8b-e087-4ab0-82e3-a4d157f1e0cc Perez-Ruiz, E. (Elisabeth)\|\|\|/items/d83c356b-f521-479f-83df-13785e169cc1 Marquez-Rodas, I. (Iván)\|\|\|/items/a59fa425-b0b0-47e3-9eb6-0543b7132a0c Rodríguez-Abreu, D. (Delvys)\|\|\|/items/ecc8f1ae-480b-428f-ac12-bf672f06fa67 Blanco, R. (Remedios)\|\|\|/items/7644d971-8a63-4eda-9012-fbd925d700cf Puertolas, T. (Teresa)\|\|\|/items/95b9743f-10df-4b17-acb4-54380eae921b Royo, M.A. (María Ángeles)\|\|\|/items/70abc417-2e22-4f7c-857a-bf26dc742cdb Rosell, R. (Rafael)\|\|\|/items/771e36b5-84e0-4ac6-9009-324f454c04b0
author2_role	author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Immunotherapy Interferon-gamma PD-1 PD-L1 Lung cancer Melanoma
topic	Immunotherapy Interferon-gamma PD-1 PD-L1 Lung cancer Melanoma
description	Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined.
publishDate	2018
dc.date.none.fl_str_mv	2018 2018-01-01 2018 2018-01-01 2023 2023-03-09
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/65643
url	https://hdl.handle.net/10171/65643
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	SAGE Publications
publisher.none.fl_str_mv	SAGE Publications
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869405468437250048
score	15,301603

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Registos relacionados